Healthy.io, Geisinger, and Boehringer Ingelheim have collaborated to conduct a groundbreaking study showcasing the impact of smartphone technology on identifying kidney diseases. The study, supported by Boehringer Ingelheim, involved 4,000 patients with diabetes and/or hypertension from Geisinger, focusing on chronic kidney disease (CKD) screening. Patients in the pilot group received either Healthy.io’s Minuteful Kidney smartphone-powered home test or a standard laboratory test, followed by patient outreach.
Presented at the American Diabetes Association’s 85th Scientific Sessions in June 2025, the findings revealed that patients using the smartphone-powered test were more likely to receive a CKD diagnosis compared to those in the control group. The results underscore the potential of smartphone-enabled testing to enhance screening compliance and improve patient outcomes, as noted by Healthy.io’s CEO, Geoff Martin.
Boehringer Ingelheim’s Senior Vice President, Brian DiDonato, emphasized the importance of early CKD detection in mitigating disease progression and cardiovascular risks. The study highlighted the significance of innovative solutions like the Minuteful Kidney program in addressing the gaps in CKD screening, especially for at-risk populations.
With limited awareness and access to comprehensive screenings contributing to poorer outcomes, the FDA-cleared Minuteful Kidney test offers a convenient solution for patients to obtain clinical-grade results rapidly. The pilot program included education and support through the Healthy.io engagement team, empowering participants to overcome barriers to care.
Dr. Alexander Chang from Geisinger highlighted the critical role of uACR testing in assessing kidney health and cardiovascular risks. The study’s increased rates of engagement, testing, and follow-up care suggest the potential of the Minuteful Kidney program to drive earlier diagnosis rates and positively impact patients’ lives.
As the healthcare landscape evolves, digital health innovations like smartphone-enabled testing are reshaping patient care delivery. The collaboration between Healthy.io, Geisinger, and Boehringer Ingelheim exemplifies how technology can revolutionize disease identification and management, ultimately improving healthcare outcomes.
By leveraging smartphone technology, healthcare providers can bridge the gap in CKD screening, ensuring timely interventions and personalized care for patients at risk. The success of the study underscores the transformative potential of digital health solutions in enhancing patient engagement, streamlining diagnostics, and optimizing treatment strategies.
📰 Related Articles
- Study Reveals ERA-Guided pET Boosts Pregnancy Success in IVF
- Study Reveals AKT Inhibitor Boosts Survival in Breast Cancer
- Novel Blood Test Predicts Diabetic Kidney Disease Risk Early
- Ultrasound Attenuation Coefficient: Key Advancement in Liver Disease Diagnosis
- UKHSA Annual Report Reveals Rising Infectious Disease Trends